Celldex Therapeutics (CLDX) News Today → Gold Mania (From Stansberry Research) (Ad) Free cldx Stock Alerts $39.92 -1.14 (-2.78%) (As of 05/10/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineCelldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Consensus Rating of "Moderate Buy" from Brokeragesamericanbankingnews.com - May 12 at 1:14 AMCelldex Therapeutics: Rising High, With Room For Further Growthseekingalpha.com - May 10 at 10:44 AMResearch Analysts Issue Forecasts for Celldex Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:CLDX)americanbankingnews.com - May 10 at 3:48 AMCelldex Therapeutics, Inc. Forecasted to Earn Q2 2024 Earnings of ($0.59) Per Share (NASDAQ:CLDX)americanbankingnews.com - May 10 at 2:48 AMQ2 2024 EPS Estimates for Celldex Therapeutics, Inc. Lifted by Analyst (NASDAQ:CLDX)americanbankingnews.com - May 10 at 2:16 AMBrokers Issue Forecasts for Celldex Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:CLDX)marketbeat.com - May 9 at 7:32 AMCelldex Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lagfinance.yahoo.com - May 8 at 9:56 AMCelldex Therapeutics' (CLDX) Buy Rating Reaffirmed at HC Wainwrightamericanbankingnews.com - May 8 at 5:34 AMCelldex Therapeutics, Inc.: Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Updatefinanznachrichten.de - May 7 at 6:55 PMUnveiling 4 Analyst Insights On Celldex Therapeuticsmarkets.businessinsider.com - May 7 at 6:55 PMCelldex Therapeutics (NASDAQ:CLDX) Earns Buy Rating from HC Wainwrightmarketbeat.com - May 7 at 8:32 AMCLDX Stock Earnings: Celldex Therapeutics Beats EPS, Misses Revenue for Q1 2024investorplace.com - May 6 at 10:08 PMCelldex Reports First Quarter 2024 Financial Results and Provides Corporate Updateglobenewswire.com - May 6 at 4:01 PMCelldex completes patient enrollment for Phase 2 urticaria trialinvesting.com - April 19 at 5:15 PMCelldex Therapeutics (NASDAQ:CLDX) Stock Rating Reaffirmed by HC Wainwrightmarketbeat.com - April 17 at 3:45 PMCelldex Hails Enrolment News, Shares Poke Aheadmsn.com - April 17 at 12:55 PMCelldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticariafinance.yahoo.com - April 17 at 12:55 PMCelldex Therapeutics (NASDAQ:CLDX) Trading 2.7% Higher marketbeat.com - April 17 at 12:20 PMCelldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticariaglobenewswire.com - April 17 at 8:01 AMDekaBank Deutsche Girozentrale Acquires Shares of 25,000 Celldex Therapeutics, Inc. (NASDAQ:CLDX)marketbeat.com - April 15 at 5:09 AMCLDX Celldex Therapeutics, Inc.seekingalpha.com - April 11 at 1:56 PMShort Interest in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Declines By 8.0%marketbeat.com - April 1 at 12:23 AMSG Americas Securities LLC Sells 31,928 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)marketbeat.com - March 29 at 4:28 AMCantor Fitzgerald Reiterates "Overweight" Rating for Celldex Therapeutics (NASDAQ:CLDX)marketbeat.com - March 22 at 2:58 PMCelldex Therapeutics, Inc. (NASDAQ:CLDX) Short Interest Updatemarketbeat.com - March 19 at 3:32 PMCLDX Aug 2024 70.000 callfinance.yahoo.com - March 17 at 9:55 PMWellington Management Group LLP Buys 300,406 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)marketbeat.com - March 17 at 4:47 AMCLDX Apr 2024 65.000 callfinance.yahoo.com - March 16 at 9:26 AMCLDX Aug 2024 50.000 callfinance.yahoo.com - March 16 at 9:26 AMCLDX Apr 2024 40.000 callfinance.yahoo.com - March 16 at 12:52 AMCLDX Jan 2025 15.000 putfinance.yahoo.com - March 16 at 12:52 AMGSA Capital Partners LLP Increases Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX)marketbeat.com - March 9 at 7:47 AMCelldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conferenceglobenewswire.com - March 8 at 7:00 AMCLDX Jan 2025 30.000 putca.finance.yahoo.com - March 6 at 6:58 PMCLDX Jan 2025 70.000 callca.finance.yahoo.com - March 6 at 6:58 PMCelldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conferencefinance.yahoo.com - March 6 at 6:58 PMCelldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Sharesfinance.yahoo.com - March 5 at 10:32 AMCelldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conferenceglobenewswire.com - March 5 at 10:30 AMCelldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Sharesglobenewswire.com - March 5 at 10:10 AMCelldex Therapeutics (NASDAQ:CLDX) Sets New 52-Week High at $53.18marketbeat.com - March 4 at 10:52 AMCelldex announces $400.4 million public stock offeringinvesting.com - March 2 at 11:22 PMCelldex Therapeutics (NASDAQ:CLDX) Sees Unusually-High Trading Volumemarketbeat.com - March 1 at 12:14 PMQ1 2024 EPS Estimates for Celldex Therapeutics, Inc. Raised by Leerink Partnrs (NASDAQ:CLDX)marketbeat.com - March 1 at 7:44 AMCelldex Therapeutics Prices Public Offering Of 8.52 Mln Shares At $47.00/shrmarkets.businessinsider.com - March 1 at 7:18 AMCharles Schwab Investment Management Inc. Buys 10,818 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)marketbeat.com - March 1 at 4:19 AMCelldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stockglobenewswire.com - February 29 at 9:14 PMCelldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Bought by Eventide Asset Management LLCmarketbeat.com - February 29 at 1:27 PMWall Street Analysts Predict a 26.53% Upside in Celldex (CLDX): Here's What You Should Knowfinance.yahoo.com - February 29 at 12:48 PMCelldex Therapeutics, Inc. (NASDAQ:CLDX) Expected to Earn FY2028 Earnings of $2.25 Per Sharemarketbeat.com - February 29 at 9:45 AMCelldex Therapeutics Announces Proposed Public Offering of Common Stockglobenewswire.com - February 28 at 4:01 PM Get Celldex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon’s New Device is About to Shock the World (Ad)Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. CLDX Media Mentions By Week CLDX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLDX News Sentiment▼0.700.58▲Average Medical News Sentiment CLDX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLDX Articles This Week▼262▲CLDX Articles Average Week Get Celldex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Myriad Genetics News Intellia Therapeutics News Neogen News QuidelOrtho News Riot Platforms News Aspira Women's Health News Lantheus News Kymera Therapeutics News Arvinas News Patterson Companies News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLDX) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsGold Set to EXPLODE!Gold Safe Exchange[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celldex Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.